Enuresis

Goodnites® and the Autism Society of America Celebrate Children's Creativity by Turning Original Artwork into Limited-Edition Custom Throw Blanket

Retrieved on: 
Monday, October 30, 2023
XL, Child, Council, Education, Football, MUST, Reading, EST, Autism Society of America, Societal and cultural aspects of autism, Research, Creativity, Friends, Caregiver, The Autism Community in Action, NO, Partnership, Enuresis, SEE, Sleep, XS, VOID, Happiness, ADHD, Toy, Residential care, Goodnites, Autism spectrum

CHICAGO, Oct. 30, 2023 /PRNewswire/ -- To every kid, an awesome day may look different. For some, it's a great day at school, while for others it's winning a soccer game or spending time with a sibling. For children who experience bedwetting, their "awesome day" may be impacted when wet sheets disrupt their otherwise restful night's sleep. Today, Goodnites®, the #1 bedwetting underwear1 brand, is celebrating children's creativity and what an awesome day means to them by launching the Awesome Days Contest.2 In partnership with the Autism Society of America, America's largest and oldest grassroots Autism organization, Goodnites is inviting children ages 17 and under, along with their caregivers, to submit a piece of original drawn artwork depicting an awesome day for the chance to have the design transformed into a limited-edition throw blanket. One Grand Prize winner will have their artwork chosen for the blanket design, receive $5,000 to put towards a bedroom makeover and receive a 1-year supply of Goodnites Bedwetting Underwear. An additional 49 applicants will be selected to receive the limited-edition throw blanket.

Key Points: 
  • For children who experience bedwetting, their "awesome day" may be impacted when wet sheets disrupt their otherwise restful night's sleep.
  • An additional 49 applicants will be selected to receive the limited-edition throw blanket.
  • Now through November 28, 2023, Goodnites and the Autism Society are inviting all children with a connection to the Autism community to visit https://goodnitesawesomedayscontest.com/ to submit a piece of original artwork.
  • The artwork should be creative, empowering, evoke feelings of happiness and positivity, and have a connection to the Goodnites brand.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) at World Sleep 2023

Retrieved on: 
Friday, October 20, 2023
FDA, Headache, Narcolepsy, Incidence, NT2, Food, Health, Vomiting, Dizziness, Epworth Sleepiness Scale, Cataplexy, Nausea, Poster, Senior, EDS, Disease, Enuresis, Avadel Pharmaceuticals, World Sleep Day, Sodium oxybate, Doctor of Pharmacy, Body mass index, Sleep, CIII, Mitigation, Patient, Central nervous system, Pharmaceutical industry, Dietary supplement, NT1

DUBLIN, Ireland, Oct. 20, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new and encore data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 15 poster presentations and two oral presentations, at World Sleep 2023, being held from October 20-25, 2023 in Rio de Janeiro, Brazil. LUMRYZ (previously known as FT218), is a U.S. Food and Drug Administration (FDA) approved extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (EDS) in adults with narcolepsy.

Key Points: 
  • “We are excited to be at this year’s World Sleep meeting with another robust display of data that supports both the established clinical benefit of LUMRYZ,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • “Quality sleep is a foundational pillar of health for people with narcolepsy, yet ~65% of patients with narcolepsy experience poor, fragmented sleep in addition to their daytime symptoms.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.
  • Most common adverse reactions (incidence > 5% and greater than placebo) reported for all doses of LUMRYZ combined were nausea, dizziness, enuresis, headache, and vomiting.

Avadel Pharmaceuticals Announces Data Supporting Clinical Profile for LUMRYZ™ at SLEEP 2023

Retrieved on: 
Wednesday, May 31, 2023
Sodium oxybate, Orphan, Abstract, AASM, Central nervous system, American Academy of Sleep Medicine, Cataplexy, Doctor of Pharmacy, Sleep, Senior, Enuresis, Mitigation, EDS, Narcolepsy, Sleep Research Society, Food and Drug Administration, Weight loss, Severe cutaneous adverse reactions, American Academy, CIII, Approximation error, Vomiting, Incidence, Dizziness, Patient, Nausea, Poster, FDA, Health, Headache, Food, Pharmaceutical industry

DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.

Key Points: 
  • DUBLIN, May 31, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a company focused on transforming medicines to transform lives, today announced new data supporting the clinical profile for LUMRYZ™ (sodium oxybate) for extended-release oral suspension (CIII) and patient preference for a once-nightly oxybate in 12 abstracts, including six oral presentations, at SLEEP 2023, the 37th annual joint meeting of the American Academy of Sleep Medicine and the Sleep Research Society, being held from June 3-7, 2023 in Indianapolis.
  • LUMRYZ was granted U.S. Food and Drug Administration (FDA) approval in May 2023, and is the first and only FDA approved once-at-bedtime oxybate for people living with narcolepsy.
  • “We are thrilled to attend SLEEP 2023 and present a broad range of data further supporting the clinical value proposition of LUMRYZ as a once-nightly option to manage EDS and cataplexy in narcolepsy, including data from our RESTORE and REST-ON trials,” said Jennifer Gudeman, PharmD, Senior Vice President, Medical and Clinical Affairs of Avadel.
  • LUMRYZ is available only through a restricted program under a Risk Evaluation and Mitigation Strategy called the LUMRYZ REMS.

Expert Pediatricians Launch Bedwetting Telehealth Platform, Vamio Health

Retrieved on: 
Friday, April 14, 2023
Telehealth, Enuresis, Pediatrics, Nocturnal enuresis, Urine, Pediatrics (journal), Silver, Health, American Academy, Research, Embarrassment, Certification, Patient, Family, Nursing

AUSTIN, Texas, April 14, 2023 /PRNewswire/ -- Nocturnal enuresis, more commonly known as bedwetting, affects five million children over the age of six in the United States, according to the American Academy of Pediatrics. Most children will outgrow bedwetting without any kind of intervention, but in some cases, it can persist into teenage years. This can cause self-esteem issues, embarrassment, and social avoidance for children and create significant stress on the family.

Key Points: 
  • Bedwetting is one of the most common chronic childhood conditions, yet access to specialized care for it is very limited.
  • Years of diagnosing and treating this condition led to Vamio Health, a telehealth bedwetting solution developed by pediatric experts and husband and wife team, Dr. Stephen Canon and Dr.
  • Dr. Danielle Sweeney is also a member of the Vamio Health medical team and a board-certified pediatric urologist.
  • "Vamio Health provides patients and their families the opportunity to speak candidly with a pediatric specialist about a sensitive condition, like bedwetting, in the comfort of their own home."

Goodnites® Announces National Campaign and Partnership with the Autism Society of America to Raise Awareness and Provide Solutions for Bedwetting Needs of Families with Neurodivergent Children

Retrieved on: 
Wednesday, March 29, 2023
Parent, Goodnites, Organization, ADHD, Nocturnal enuresis, Shame, Partnership, Enuresis, Autism Society of America, Autism spectrum, Education, Residential care

NEENAH, Wis., March 29, 2023 /PRNewswire/ -- Goodnites, the #1 bedwetting underwear1 brand, announced a new partnership with the Autism Society of America, America's largest and oldest grassroots Autism organization, to educate, support, and provide solutions for families of children with Autism who are in need of a longer-term bedwetting solution. Since inventing the absorbent bedwetting underwear category in 1994, Goodnites has been committed to empowering users to have a dry night's sleep and wake up awesome! Its bedwetting underwear is designed to provide children ages 3 to 17 a dry night's sleep with 35% fewer leaks2. While bedwetting is a common occurrence among most children, children with Autism and/or ADHD may face a longer experience with nocturnal enuresis, commonly known as bedwetting. In honor of Autism Acceptance Month this April, Goodnites will donate $150,000 to the Autism Society of America to support education and community efforts throughout 2023. As part of the programming, the brand is also unveiling new proprietary research illustrating the impact of bedwetting on families of children with ADHD and/or Autism, sharing awareness-driving content across digital channels, and amplifying influential voices in the neurodivergent and parenting space to help reduce the shame and stigma around bedwetting through education.

Key Points: 
  • Its bedwetting underwear is designed to provide children ages 3 to 17 a dry night's sleep with 35% fewer leaks2.
  • While bedwetting is a common occurrence among most children, children with Autism and/or ADHD may face a longer experience with nocturnal enuresis, commonly known as bedwetting.
  • In honor of Autism Acceptance Month this April, Goodnites will donate $150,000 to the Autism Society of America to support education and community efforts throughout 2023.
  • The survey uncovered the physical, emotional, relational, and mental impact that bedwetting has on families of children with Autism and/or ADHD.

Avadel Pharmaceuticals Announces Publication of Real-World Data Highlighting the Risk of Accidental Dosing Errors with Immediate-Release Twice-Nightly Oxybates

Retrieved on: 
Tuesday, January 24, 2023
Bradycardia, Vomiting, Narcolepsy, Food, Accidental, Emergency medical services, Dizziness, CNS, Seizure, Nausea, Sleep, Risk, Hospital, Depression, Hypoventilation, Patient, Delirium, Falls, Regulation of tobacco by the U.S. Food and Drug Administration, FDA, Confusion, US Foods, Senior, Enuresis, AES, Somnolence, Pharmaceutical industry

DUBLIN, Ireland, Jan. 24, 2023 (GLOBE NEWSWIRE) -- Avadel Pharmaceuticals plc (Nasdaq: AVDL), a biopharmaceutical company focused on transforming medicines to transform lives, today announced the publication of real-world data describing the risk of accidental dosing errors with immediate-release twice-nightly oxybate. The paper, titled “Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data From the US Food and Drug Administration Adverse Event Reporting System,” was published in Drugs — Real World Outcomes and can be accessed here.

Key Points: 
  • The paper, titled “Evidence of Accidental Dosing Errors with Immediate-Release Sodium Oxybate: Data From the US Food and Drug Administration Adverse Event Reporting System,” was published in Drugs — Real World Outcomes and can be accessed here.
  • Nearly one-fourth of these cases resulted in emergency medical services or emergency department visits, and another 27% resulted in hospitalization.
  • The medical and patient community should be aware of this risk with immediate-release oxybates, as it is not currently described in the labeling.
  • An extended-release once-nightly sodium oxybate product that eliminates a second, middle-of-the-night dose, could potentially mitigate these risks.”

Assessment of the Global Nocturnal Enuresis Pipeline 2020 - ResearchAndMarkets.com

Retrieved on: 
Friday, July 3, 2020
Health, Pharmaceutical, Medical specialties, Medicine, Clinical medicine, Toilet training, Urine, Sleep disorders, Childhood, Nocturnal enuresis, Urology, Enuresis

The "Nocturnal Enuresis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Nocturnal Enuresis - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • A detailed picture of the Nocturnal Enuresis pipeline landscape is provided, which includes the disease overview and Nocturnal Enuresis treatment guidelines.
  • The assessment part of the report embraces in-depth Nocturnal Enuresis commercial assessment and clinical assessment of the Nocturnal Enuresis pipeline products from the pre-clinical developmental phase to the marketed phase.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Nocturnal Enuresis.

Global Urinary Incontinence Devices Market to 2023: Market Size is Expected to Reach $3.6 Billion

Retrieved on: 
Wednesday, June 13, 2018
Urinary incontinence, Medicine, Urology, Clinical medicine, Stress incontinence, Incontinence, Continence, Fecal incontinence, Urinary system, Incontinence underwear, Enuresis

The "Global Urinary Incontinence Devices Market Analysis (2017-2023)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Urinary Incontinence Devices Market Analysis (2017-2023)" report has been added to ResearchAndMarkets.com's offering.
  • The Global Urinary Incontinence Devices Market size is expected to reach $3.6 billion by 2023, rising at a market growth of 11.6% CAGR during the forecast period.
  • Urinary incontinence is an unintentional leakage of urine, and it is differentiated into four types, namely, stress urinary incontinence, urge urinary incontinence, overflow urinary incontinence, and functional urinary incontinence.
  • The category segment includes External Urinary Incontinence Devices and Internal Urinary Incontinence Devices.

Mictoryl® Pediatric (propiverine hydrochloride) now covered by several public drug plans to treat symptoms associated with overactive bladder

Retrieved on: 
Thursday, June 7, 2018
Medicine, Surgery, Clinical medicine, Urinary incontinence, Surgical specialties, Urinary bladder disorders, Overactive bladder, Urology, Urinary bladder, Urodynamic testing, Enuresis

Mictoryl Pediatric is indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.

Key Points: 
  • Mictoryl Pediatric is indicated for the symptomatic treatment of urinary incontinence and/or increased urinary frequency and urgency in pediatric patients, from the age of 5 years, with overactive bladder.
  • "There continues to be a need for new pediatric-specific therapies for children suffering from overactive bladder in Canada," said ric Gervais, executive vice-president of Duchesnay.
  • "We are pleased with these recent decisions to include Mictoryl Pediatric in certain public drug plans, making a treatment with years of research and European market experience more accessible to Canadian families of children with overactive bladder."
  • Mictoryl Pediatric was developed by Apogepha, a leading german pharmaceutical company, specializing in urology.